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ABSTRACT
Introduction: Globally, respiratory syncytial
virus (RSV) is the most common cause of serious
lower respiratory tract infections (LRTIs) inyoung
children, and is a major cause of hospital
admission in children\1 year of age. The study
evaluated the severity of RSV-associated LRTI
disease among premature (\36 weeks gestational
age (GA)) and term children\1 year of age and
assessed the influence of GA on outcomes of RSV
LRTI hospitalization in Central and Eastern
Europe (CEE).
Methods: Retrospective cohort survey of
children \1 year of age hospitalized with an
LRTI during the periods of October 2009 to
April 2010 or October 2010 to April 2011 in 12
CEE countries.
Results: Across two RSV seasons, 3474
evaluable children were hospitalized because
of LRTI; 757 (21.8%) were premature and 2679
(77.1%) were term. RSV tests were positive in
1423 (42.4%) cases, of which 266 (18.7%) were
premature and 1034 (72.7%) were term
children. Among the RSV-positive patients,
premature children had a significantly longer
hospital stay (17 vs 8 days; P\0.001), were
more frequently hospitalized in the intensive
care unit (ICU) (41.4% vs 12.6%) and remained
in the ICU significantly longer (13 vs 6 days;
P\0.001) compared with term children.
Premature children had a 3.3-fold (95% CI,
2.66–4.09) increased risk for ICU hospitalization
compared with term children (P\0.001). ICU
hospitalization, prolonged hospital stay,
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supplemental oxygen administration and death
occurred significantly more frequently among
children with lower vs higher GA.
Conclusion: RSV infection is associated with
substantial morbidity in CEE among premature
and term children. The attributable morbidity,
however, is significantly greater among
premature children compared with term
children, including longer hospital stays and
more frequent and longer stays in the ICU.
These findings are consistent with previously
published data outside of CEE, demonstrating
prematurity as a significant and independent
predictor for severe RSV disease.
Funding: AbbVie Inc.
Keywords: Gestational age category; ICU stay;
Prematurity; Respiratory syncytial virus; RSV
hospitalization
INTRODUCTION
Globally, respiratory syncytial virus (RSV) is a
major cause of hospital admission in infants
\1 year of age [1]. Mortality data demonstrate
that RSV kills more infants in this age group
than any other single pathogen with the
exception of malaria [2]. Environmental
factors and individual characteristics carrying
increased risk of RSV-associated acute
respiratory tract infections include low birth
weight, being a member of a multiple birth,
smoking during pregnancy, having siblings, day
care attendance (or sibling attendance), living
in a crowded household, low parental
education, second-hand smoke exposure,
history of atopy and lack of breastfeeding
[3–10]. Notably, being male carries a risk ratio
of 1.425:1 compared with being female [11].
Certain high-risk groups including premature
infants, infants with bronchopulmonary
dysplasia (more commonly referred to as
chronic lung disease of prematurity) and those
with congenital heart disease are particularly
vulnerable to severe RSV disease [12, 13]. RSV is
more likely to progress to the lower respiratory
tract and cause more serious disease in these
high-risk children compared with otherwise
healthy term children. Furthermore, the
course of illness tends to be more severe in
these children versus otherwise healthy term
children, and is associated with higher rates of
hospitalization, intensive care unit admission,
mechanical ventilation and death [14–18].
The RSV burden of disease is relatively well
characterized in Western Europe; however, there
are limited epidemiologic data available for
Central and Eastern Europe (CEE) and the
developing world. Mortality data are especially
difficult to ascertain as themajority of children in
developing countries die outside of the hospital
setting [19]. Characterization of children with
severeRSVdisease is critically important to inform
healthcareauthorities to target interventions that
maximize population health. The present study
aimed to characterize RSV disease incidence and
severity among premature and term children in
CEE. We evaluated the severity of RSV-associated
lower respiratory tract infection (LRTI) disease in
children\1 year of age during the 2009–2010 and
2010–2011 RSV seasons and investigated the
influence of gestational age (GA) on the




This retrospective, epidemiologic, cohort survey
included children \1 year of age hospitalized
with an LRTI during the periods October 2009
to April 2010 and October 2010 to April 2011.
Children with duplicate records were excluded.
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Patients were hospitalized in the pediatric
intensive care units and pediatrics wards of
general, university, pediatric or other types of
hospitals at 48 study sites across 12 CEE
countries (Estonia, Lithuania, Hungary,
Slovenia, Croatia, Serbia, Bosnia/Herzegovina,
Bulgaria, Czech Republic, Slovakia, Romania,
and Ukraine). Data collection was performed on
day of hospital discharge or during first checkup
visit after LRTI hospitalization. An enrollment
form was used to collect demographic and
clinical data from enrolled patients.
The study was conducted in compliance with
any applicable national or institutional ethical
and/or regulatory requirements. All procedures
followed were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1964. Local law requirements for monitoring,
notification/submission of an epidemiologic
survey to the responsible ethics committee
and/or regulatory body were followed, and
ethical approval was obtained in the
participating countries according to national
legislation. The study sponsor vouches for the
veracity of the multiple ethical approvals. The
patient’s parent, guardian or legal
representative provided oral/written
authorization to the investigator to use and/or
disclose personal and/or health data.
Study Endpoints, Outcome Measurements
and Definitions
The primary endpoint was to evaluate the
severity of RSV-associated LRTI disease in
premature and term children. Primary
outcomes included duration of hospitalization
and the incidence, duration and risk of
intensive care unit (ICU) hospitalization.
Secondary endpoints included the assessment
of the influence of GA on the treatment,
complications and outcomes of RSV LRTI
hospitalization. Secondary outcomes included
the use of supplemental oxygen administration,
use of bronchodilators, duration of
hospitalization, the incidence and duration of
ICU hospitalization and death.
LRTI was defined as a diagnosis of pneumonia
and/or bronchiolitis according to individual
hospital/physician procedures. Radiographic
evidence of LRTI was not collected. RSV-positive
children were defined as all children who had an
LRTI hospitalization with RSV-positivity
confirmed by the RSV rapid diagnostic test.
Because RSV testing was not standardized across
the study sites, inter-site quality analysis was not
performed within the study group. RSV-positive
children with a known GA B36 weeks were
defined as premature. RSV-positive children
with a known GA C37 weeks and no other risk
factors (congenital heart disease,
bronchopulmonary dysplasia, Down syndrome
or neuromuscular disease) were defined as term
children. Gestational age was categorized into
subgroups, based on World Health Organization
criteria [20], for further analysis of the impact of
preterm birth on outcomes: extremely preterm
(\28 weeks), very preterm (28 to\32 weeks) and
moderate preterm (32–36 completed weeks of
gestation). Congenital heart disease,
bronchopulmonary dysplasia, Down syndrome
and neuromuscular disease were not uniformly
defined or standardized in the protocol.
Diagnoses of these conditions were based on the
individual physician’s experience and local
practice guidelines.
Statistical Analysis
Standard descriptive statistics were used to
describe the data: counts and percentages for
categorical data, mean and standard deviation
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for continuous data, and absolute frequency for
incidence of cases. The denominator used to
determine the incidence of ICU hospitalization
and death was the total population of children
\1 year of age hospitalized with an LRTI at
participating sites during the study periods.
Calculation of incidence did not include
compensation for the use of seasonal data
versus year-round data.
The type of admission diagnosis was
compared between groups via two-sided
Chi-square tests on a 5% level of significance.
Duration of hospitalization and duration of
supplemental oxygen administration was
compared between groups by means of
two-sided t tests on a 5% level of significance.
The influence of admission diagnosis on the
observed effects was investigated by means of
two-sided t tests on a 5% level of significance
[equivalent to a one-way analysis of variance
(ANOVA) with group in the model] with
admission diagnosis as an additional factor.
Duration of hospitalization and duration of
supplemental oxygen administration were
compared between groups (RSV-positive and
RSV-negative, RSV-positive premature and
RSV-negative premature, RSV-positive
premature and RSV-positive term). To adjust
for the influence of admission diagnosis, this
model was extended to a two-factor ANOVA
with group and admission diagnosis in the
model. In large study populations such as
these, the two-sided t test (one-way ANOVA)
and two-factor ANOVA are robust against
deviations from the normality of assumption
and homogeneity of variances assumption.
For the endpoint of ICU hospitalization, the
relative risk and associated two-sided
asymptotic 95% CIs were derived to compare
the risk of ICU hospitalization between the
groups. A Chi-square test was performed to
compare the occurrence of ICU hospitalizations
between groups at a 5% level of significance.
A Cochran–Mantel–Haenszel test was used post
hoc to adjust for admission diagnosis
differences between groups. A Chi-square test,
Cochran–Mantel–Haenszel test and relative risk
with associated two-sided asymptotic 95% CIs
were also performed for the occurrence of
supplemental oxygen administration and
death.
The influence of GA at birth on admission
diagnosis, ICU hospitalization, use of
bronchodilators and oxygen administration
was compared between groups using two-sided
Chi-square tests at a 5% level of significance.
The influence of GA at birth on the duration of
hospitalization, duration of ICU hospitalization
and duration of oxygen administration was
assessed using analysis of variance at the 5%
level of significance. All statistical analyses were
carried out by means of the SAS package
(version 9.2) (GKM Gesellschaft fu¨r
Therapieforschung mbH, Munich, Germany).
RESULTS
During the study period of October 2009–April
2010 and October 2010–April 2011, overall,
3841 records were collected from 48 sites
across 12 CEE countries. Among them, 3474
children (90.4%) fulfilled the case definition of
a documented hospitalized LRTI and were
enrolled in the study (Fig. 1). Of the 3474
evaluable children, 757 children (21.8%) were
premature (B36 weeks GA) and 2679 (77.1%)
were term. The majority of the population was
male (58.3%) and younger than 6 months
(69.1%) at the time of admission. RSV
prophylaxis had been administered in 2%
(n = 68) of the entire cohort. Demographic
and clinical characteristics of the study cohort
are summarized in Table 1.
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A rapid RSV test was performed in 3354
(96.5%) cases and RSV tests were positive in
1423 (42.4%). Of the RSV-positive cases, 266
(18.7%) were premature children and 1034
(72.7%) were term children with no risk
factors or chronic diseases. RSV prophylaxis
had been administered in 11 RSV-positive cases,
among them 9 children with GA\33 weeks and
2 term children. A comparison of the baseline
admission demographics, clinical characteristics
and outcomes of RSV LRTI hospitalization
between premature and term children is
illustrated in Table 2.
Significant differences in the diagnosis at
admission were observed between premature
and term children. Premature children were
more frequently hospitalized due to pneumonia
(37.6% vs 20.0%) and term children were more
frequently hospitalized due to bronchiolitis
(48.5% vs 71.2%; P\0.001). Hospital stays
were significantly longer for premature
children compared with term children (17 vs
8 days; P\0.001; P value adjusted for admission
diagnosis: \0.001). Premature children had a
3.3-fold (95% CI: 2.66, 4.09) increased risk for
ICU hospitalization compared with term
children (P\0.001); after adjustment for
admission diagnosis (including only those
admitted with a diagnosis of either pneumonia
or bronchiolitis), risk was increased 2.8-fold
(95% CI: 2.23, 3.47; P\0.001). ICU
hospitalizations were more frequent for
premature children (41.4% vs 12.6%; P value
not determined), and ICU stays were longer (13
vs 6 days; P\0.001) compared with term
children (P value adjusted for admission
diagnosis:\0.001).
Premature children had a 1.6-fold (95% CI:
1.43, 1.74) increased risk of receiving
supplemental oxygen compared with term
children (P\0.001); after adjustment for
admission diagnosis, risk was 1.6-fold greater
(95% CI: 1.44, 1.78; P\0.001). Compared with
term children, oxygen was administered in
premature children markedly more frequently
(72.9% vs 46.3%; P value not determined) and
for a significantly longer mean duration (9 vs
4 days; P\0.001; P value adjusted for admission
diagnosis:\0.001).
Evaluation of RSV LRTI Hospitalization
by Gestational Age
GA was reported for 1412 (99.2%) children
hospitalized for RSV LRTI hospitalized
Fig. 1 Disposition of study population. *Children who
met the case deﬁnition had to be \1 year of age and
hospitalized with a diagnosis of bronchiolitis and/or
pneumonia within the observational periods October
2009 through April 2010 or October 2010 through April
2011. GA gestational age, RSV respiratory syncytial virus
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Age at admissiona, month, mean
(SD)
5 (3)
Age category at admission, month, n (%)
0–\6 2400 (69.1)
6–12 1074 (30.9)
Gestational ageb, week, mean (SD) 36 (2)






BW, g, mean (SD) 2998 (841)





(1000 g B BW\1500 g)
176 (5.1)
Low BW
(1500 g B BW\2500 g)
482 (13.9)
Normal BW
(2500 g B BW B 4200 g)
2592 (74.6)
High BW (BW[4200 g) 114 (3.3)
Unknown 9 (0.3)
Diagnosis at admission, n (%)
Bronchiolitis only 1983 (57.1)
Pneumonia only 1183 (34.1)








Risk factors for severe RSV infection, n (%)
Premature (GA B36 week) 757 (21.8)
Congenital heart disease 166 (4.8)
Bronchopulmonary dysplasia 145 (4.2)
Neuromuscular disease 108 (3.1)
Duration of hospitalization, day,
mean (95% CI)
10.8 (10.4–11.2)






ICU hospitalization, n (%) 671 (19.3)
Length of ICU stay, dayd, mean
(95% CI)
11.0 (9.9–12.1)
Supplemental oxygen use, n (%) 1563 (45.0)
Duration of supplemental oxygen
use, daye, mean (95% CI)
6.4 (5.9–6.9)
Bronchodilator use, n (%) 2698 (77.7)
Duration of bronchodilator use,
dayf, mean (95% CI)
7.4 (7.1–7.6)
Patient outcome at discharge, n (%)
Complete recovery 1623 (46.7)
Improvement 1782 (51.3)
Death 30 (0.9)
Transfer to another hospital 21 (0.6)
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children. A comparison of the baseline
admission demographics, clinical
characteristics and outcomes of RSV LRTI
hospitalization between the GA strata is
illustrated in Table 3. No substantial
differences in age at admission were observed
among the considered strata. The proportion of
children with an admission diagnosis of
bronchiolitis (with or without pneumonia)
significantly increased through the GA strata,
ranging from 34.3% in the B28-week stratum to
78.9% in the C37-week stratum (P\0.001). The
mean duration of hospitalization decreased
significantly through the GA strata, ranging
from 29 days in the B28-week stratum to 9 days
in the C37-week stratum (P\0.001).
The proportion of cases requiring ICU
hospitalization decreased significantly through
the GA strata, ranging from 54.3% in the
B28-week stratum to 14.1% in the C37-week
stratum (P\0.001). The length of stay in the ICU
was comparable in the33- to36-week stratumand
the C37-week stratum (7 days for both groups);
however, the duration was significantly longer in
childrenwithGA\33 weeks (P\0.001;17 days in
the 29- to 32-week stratum and 19 days in the
B28-week stratum). Overall, the observed
differences in length of stay in the ICU were
statistically significant (P\0.001) across the GA
strata.
The proportion of children requiring
supplemental oxygen significantly decreased
through the GA strata, ranging from 80.0% in
the B28-week stratum to 47.6% in the
C37-week stratum (P\0.001). Duration of
supplemental oxygen use also significantly
decreased as GA increased, ranging from
19 days in the B28-week stratum to 5 days in
the C37-week stratum (P\0.001). The
proportion of children treated with
bronchodilators increased through the strata,
ranging from 60.0% in the B28-week stratum to
83.1% in the C37-week stratum. Regarding
outcome at discharge, the proportion of
children who recovered completely ranged
from 31.4% in the B28-week stratum to 52.4%
in the 33- to 36-week stratum. There were 12
deaths, with the proportion of deaths
decreasing with increasing GA. Among them,
six premature children (three deaths in each of
the B28- and 29- to 32-week strata, one death in
the 33- to 36-week stratum) and five term
children died.
DISCUSSION
The main objective of this multinational study
was to characterize the severity of RSV-associated
LRTI disease among premature and term CEE
children younger than 1 year across two RSV
seasons. Our analysis of 1423 RSV-positive
children demonstrates substantial morbidity in
the first year of life among children hospitalized
for RSV LRTI in CEE. Consistent with other
geographic regions, premature children with





BW birth weight, GA gestational age, ICU intensive care
unit, RSV respiratory syncytial virus
a Age was recorded on the case report form. The mean
calculation category 0–6 months was analyzed as
3 months; the age category 6–12 months was analyzed as
9 months
b Gestational age was recorded on the case report form
c Percentages were calculated on 3354 cases with RSV
rapid tests
d Only for patients who were hospitalized
e Only for patients who used oxygen
f Only for patients who used bronchodilators
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Table 2 Baseline admission demographics, clinical characteristics and outcomes of RSV LRTI hospitalization between
premature and term children
Characteristic Premature (n5 266) Term (n5 1034) P value
Sex, n (%) ND
Male 147 (55.3) 591 (57.2)
Female 114 (42.9) 426 (41.2)
Unknown 5 (1.9) 17 (1.6)
Age at admission, n (%) ND
0–\6 months 203 (76.3) 770 (74.5)
6–12 months 63 (23.7) 264 (25.5)
Presence of chronic diseases at admission, n (%) ND
Any chronic disease 91 (34.2) 0
Congenital heart disease 27 (10.2) 0
Bronchopulmonary dysplasia 41 (15.4) 0
Neuromuscular disease 18 (6.8) 0
Other chronic diseases 42 (15.8) 0
RSV prophylaxis, n (%) 9 (3.4) 2 (0.2) ND
Diagnosis at admission, n (%) \0.001*
Bronchiolitis only 129 (48.5) 736 (71.2)
Pneumonia only 100 (37.6) 207 (20.0)
Both diagnoses 37 (13.9) 91 (8.8)
Duration of hospitalization, day, mean (SD) 17 (20) 8 (5) \0.001
ICU hospitalization, n (%) 110 (41.4) 130 (12.6) ND
Length of ICU stay, day, mean (SD) 13 (15) 6 (5) \0.001
Supplemental oxygen use, n (%) 194 (72.9) 479 (46.3) ND
Duration of supplemental oxygen use, day, mean (SD) 9 (12) 4 (3) \0.001
Outcome at discharge, n (%) ND
Complete recovery 122 (45.9) 418 (40.4)
Improved 132 (49.6) 601 (58.1)
Death 7 (2.6) 3 (0.3)
Transfer to other hospital 3 (1.1) 6 (0.6)
Unknown 2 (0.8) 6 (0.6)
ICU intensive care unit, LRTI lower respiratory tract infection, ND not determined, RSV respiratory syncytial virus
* Statistical signiﬁcance was determined using two-sided Chi-square tests on a 5% level of signiﬁcance
 Statistical signiﬁcance was determined using analysis of variance on a 5% level of signiﬁcance
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Table 3 Baseline admission demographics, clinical characteristics and outcomes of RSV LRTI hospitalization between
gestational age at birth









Sex, n (%) ND
Male 15 (42.9) 60 (69.8) 72 (49.7) 663 (57.9)
Female 20 (57.1) 26 (30.2) 68 (46.9) 465 (40.6)
Unknown 0 0 5 (3.4) 18 (1.6)
Age at admission, n (%) ND
0–\6 months 27 (77.1) 70 (81.4) 106 (73.1) 857 (74.8)
6–12 months 8 (22.9) 16 (18.6) 39 (26.9) 289 (25.2)
Diagnosis at admission, n (%) \0.001*
Bronchiolitis only 12 (34.3) 37 (43.0) 80 (55.2) 788 (68.8)
Pneumonia only 23 (65.7) 41 (47.7) 36 (24.8) 241 (21.0)
Both diagnoses 0 8 (9.3) 29 (20.0) 117 (10.2)
Chronic diseases at admission, n (%) ND
Any chronic disease 16 (45.7) 44 (51.2) 31 (21.4) 107 (9.3)
Congenital heart disease 4 (11.4) 9 (10.5) 14 (9.7) 34 (3.0)
Bronchopulmonary dysplasia 12 (34.3) 25 (29.1) 4 (2.8) 0
Neuromuscular disease 2 (5.7) 11 (12.8) 5 (3.4) 18 (1.6)
Other chronic diseases 7 (20.0) 17 (19.8) 18 (12.4) 76 (6.6)
RSV prophylaxis, n (%) 6 (17.1) 3 (3.5) 0 2 (0.2) ND
Duration of hospitalization, day,
mean (SD)
29 (34) 24 (21) 11 (10) 9 (7) \0.001
1–3, n (%) 1 (2.9) 1 (1.2) 8 (5.5) 93 (8.1)
4–7, n (%) 8 (22.9) 11 (12.8) 44 (30.3) 494 (43.1)
8–14, n (%) 11 (31.4) 26 (30.2) 68 (46.9) 466 (40.7)
C15, n (%) 15 (42.9) 48 (55.8) 23 (15.9) 91 (7.9)
ICU hospitalization, n (%) 19 (54.3) 42 (48.8) 49 (33.8) 162 (14.1) \0.001*
Length of stay in ICU, day, mean
(SD)
19 (21) 17 (18) 7 (6) 7 (6) \0.001
Supplemental oxygen use, n (%) 28 (80.0) 67 (77.9) 99 (68.3) 546 (47.6) \0.001*
Duration of supplemental oxygen use,
day, mean (SD)
19 (23) 12 (10) 5 (3) 5 (5) \0.001
Use of bronchodilators, n (%) 21 (60.0) 60 (69.8) 118 (81.4) 952 (83.1)
Infect Dis Ther (2016) 5:125–137 133
a more severe course of RSV disease compared
with their term-delivered counterparts. These
results provide further evidence that, like
exposure to second-hand smoke, being male,
and living with siblings, prematurity is a
near-universal risk factor for severe
RSV-associated infection [3–9, 11].
Premature children were more frequently
hospitalized due to pneumonia (with and
without bronchiolitis) than term children
(51.5% vs 28.8%; P\0.001). The observed
differences in admission diagnosis might
reflect different hospitalization strategies for
premature and term children. We cannot
determine from this analysis whether
premature and term children presenting with
similar symptoms were equally likely to be
hospitalized.
Premature children exhibited longer stays in
the hospital, more frequent and longer stays in
the ICU and more frequent and longer
administration of supplemental oxygen than
term children; even after adjusting for the
admission diagnosis, the differences remain
significant (P\0.001). In fact, the risk of an
ICU stay was 2.8 times higher in premature than
term children after adjusting for admission
diagnosis. Furthermore, decreasing GA at birth
was found to increase risk for ICU
hospitalization, prolonged duration of
hospitalization, supplemental oxygen
administration and death. Even among late
premature children (33–36 weeks gestation),
the course of RSV-positive LRTI disease was
more severe than that of full-term children.
Compared with term children, a greater
proportion of late premature children
(33–36 weeks gestation) with RSV LRTI were
hospitalized in the ICU (33.8% vs 14.1%), spent
C15 days in the hospital (1.4% vs 1.0%) and
required supplemental oxygen administration
(68.3% vs 47.6%). These findings are consistent
with previous studies inWestern Europe and the
United States that reported a high rate of
healthcare utilization for RSV-positive LRTI
among premature children 33–35 weeks
gestation [15, 21].
The strength of this study is that it
investigates a large multinational cohort of
children from a geographical area that has not
been previously well characterized. However,
this study has several key limitations. We
Table 3 continued









Outcome at discharge ND
Complete recovery 11 (31.4) 35 (40.7) 76 (52.4) 464 (40.5)
Improved 19 (54.3) 46 (53.5) 67 (46.2) 663 (57.9)
Death 3 (8.6) 3 (3.5) 1 (0.7) 5 (0.4)
Transfer to other hospital 1 (2.9) 2 (2.3) 0 7 (0.6)
Unknown 1 (2.9) 0 1 (0.7) 7 (0.6)
Gestational age was reported for 1412 of the 1423 children with RSV infections
ICU intensive care unit, LRTI lower respiratory tract infection, ND not determined, RSV respiratory syncytial virus
* Statistical signiﬁcance was determined using two-sided Chi-square tests on a 5% level of signiﬁcance
 Statistical signiﬁcance was determined using analysis of variance on a 5% level of signiﬁcance
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acknowledge that the study data from the 2009
to 2010 and 2010 to 2011 RSV seasons may not
appear current. However, to our knowledge, no
substantial developments in the medical practice
of prevention or care of these children for RSV
LRTI, including the use of prophylaxis with
palivizumab, have since occurred in CEE that
would change study results if conducted today.
As such, the clinical relevance and severity of
RSV-associated LRTI disease likely has remained
the same. RSV reinfection is a common
occurrence [22] and we were not able to
account for possible reinfections in this study.
In addition, the number of collected cases in our
study was affected by factors associated with the
recruitment process, such as time resources of
the investigators, availability of diagnostic tests,
strategies for identifying cases and obtaining
consent for study participation. Given that data
were collected on the day of hospital discharge
or during the first checkup visit after LRTI
hospitalization, bias may have been introduced.
The RSV rapid diagnostic tests that utilize
antigen capture technology have a sensitivity
and specificity of approximately 90%. Data
regarding timing of the RSV rapid test during
the course of the disease were not captured. As a
result, the true proportion of RSV infections may
have been underestimated. Use of univariate
analyses, instead of multivariate analyses, may
have increased the likelihood of an analysis
reaching statistical significance by chance.
Furthermore, the lack of adjustment for
potential confounders or other potential risk
factors limits the value of the univariate
assessment of potential risk factors. However,
the primary endpoint was to evaluate the
severity of RSV-associated LRTI disease in
premature and term children. Primary
outcomes included duration of hospitalization,
and the incidence, duration and risk of ICU
hospitalization. Because investigation of the
potential risk factors was an additional,
exploratory data analysis in the statistical
analysis plan and the findings would not have
impacted the primary endpoint of this study, we
did not pursue a multivariate analysis of these
factors. Because diagnosis of LRTI was based on
individual physician/hospital practice, local or
regional differences may also have introduced
bias. National and regional differences in
treatment practice and healthcare systems,
especially the criteria for hospitalization, may
have affected our overall risk factor findings and
may also affect assessments of congenital heart
disease, bronchopulmonary dysplasia, Down
syndrome and neuromuscular disease, ICU
admittance and use of supplemental oxygen
and bronchodilators.
CONCLUSION
Overall, the results of this study demonstrate the
importance of RSV as a significant contributor to
pediatric morbidity in the first year of life and
confirm results from studies outside of CEE that
show that prematurely born children
hospitalized for RSV-related infections have a
more severe course of disease than full-term
children, as demonstrated by longer stays in the
hospital and more frequent and longer stays in
the ICU than term children without risk factors.
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